MSTN

In one line: MSTN makes myostatin — a protein your muscles release to tell themselves to stop growing; switch the gene off and muscle runs away with itself, which is why a single broken gene turns up in super-muscled cattle, faster dogs, and an extraordinarily strong child — and why "blocking the brake" is one of the biggest, and most humbling, bets in muscle medicine.

---

The gene

MSTN — also written GDF8 (growth/differentiation factor 8) — sits on the long arm of chromosome 2, at 2q32.2. It codes for myostatin, a small secreted protein of the TGF-β superfamily. The counterintuitive part is the direction it works in: muscle cells make myostatin, release it, and it acts straight back on muscle to limit how much it grows. Myostatin isn't the engine of muscle — it's the brake. (This is the trap the whole episode is built to state correctly: losing myostatin increases muscle.)

The hunt

The brake was found by removing it. In 1997, Alexandra McPherron, Ann Lawler, and Se-Jin Lee at Johns Hopkins deleted the gene in mice; the knockout animals grew individual muscles two to three times normal size — through a combination of hyperplasia (more fibres) and hypertrophy (bigger fibres) — and the press dubbed them the "mighty mice." Nature, it turned out, had run the experiment already. The same year, McPherron and Lee showed that two famously "double-muscled" cattle breeds carry inactivating myostatin mutations: the Belgian Blue an 11-nucleotide deletion that wrecks the protein, the Piedmontese a missense change to an invariant cysteine. In 2007, Dana Mosher and colleagues found a 2-bp deletion in the whippet: dogs with one broken copy are more muscular and measurably faster racers, while two copies produce a grossly over-muscled "bully whippet." And in 2004, Markus Schuelke's team in Germany described a baby boy, born extraordinarily muscular, homozygous for a myostatin splice mutation — strong (he held a 3-kg weight in each outstretched arm by age four) and, at the time of report, healthy. The tabloids called it the "Hercules gene."

The mechanism

Myostatin is a signalling messenger. It binds the activin type-II receptor (ActRIIB) on the muscle-cell surface; that recruits a type-I receptor and trips an intracellular relay — the SMAD2/3 pathway — which holds the muscle's own stem cells (satellite cells) and its growth programs in check. Knock out the gene and that "stop" is never sent, so muscle does two things at once: it forms more fibres and makes each one bigger. The same logic explains every animal above — different DNA lesions, one disabled brake.

The stakes, and the frontier

If turning the gene off builds muscle in the healthy, could blocking myostatin rescue muscle in the sick? That became one of the great bets in muscle medicine — antibodies, ligand/receptor traps, and gene therapies aimed at Duchenne muscular dystrophy, spinal muscular atrophy, and age-related wasting (sarcopenia/cachexia). The results have been humbling. The drugs reliably add muscle — but again and again, that extra muscle hasn't translated into real-world strength or function (Pfizer's domagrozumab, for example, increased muscle volume on MRI in DMD yet missed its stair-climb endpoint). The most encouraging case is apitegromab for SMA, which showed genuine functional benefit in the Phase 3 SAPPHIRE trial — but as of 2026 no myostatin-targeting drug has been approved (apitegromab's 2025 setback was a manufacturing-facility issue, not its efficacy data; it was resubmitted in 2026). The biology is vivid and proven; turning it into medicine is the open thread.

Sources

Full claim-by-claim evidence is in references.md. Primary anchors:

• McPherron, Lawler & Lee 1997, Nature 387:83 — myostatin (GDF8) knockout mice; muscles 2–3× via hyperplasia + hypertrophy.
• McPherron & Lee 1997, PNAS 94:12457 — double-muscling in Belgian Blue (11-nt deletion) and Piedmontese (missense) cattle.
• Mosher et al. 2007, PLoS Genetics 3(5):e79 — whippet 2-bp MSTN deletion; heterozygotes faster, homozygotes "bully."
• Schuelke et al. 2004, NEJM 350:2682 — homozygous MSTN mutation, gross muscle hypertrophy in a child.
• NCBI Gene 2660 / OMIM 601788 — MSTN locus 2q32.2; myostatin a TGF-β-family negative regulator of muscle mass.
• Wagner et al. 2020, Neuromuscul Disord — domagrozumab adds muscle but misses the DMD functional endpoint; Scholar Rock 2025–26 — apitegromab SAPPHIRE result and pending FDA status.

Accuracy note (the traps the fact-gate caught): (1) Direction of effect — myostatin is a brake; losing it increases muscle (the episode never calls it "the gene that builds muscle"). (2) No approval yet — as of 2026 no myostatin drug is approved; narration stays "still awaits approval." (3) Whippet dose — one broken copy = faster racer, two = "bully whippet." (4) The child — only what NEJM reported (strong and healthy at the time); no lifelong claims. (5) "Hercules gene" is a popular nickname, not an official term.